238 related articles for article (PubMed ID: 16411385)
1. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice.
Begbie ME; Mamdani A; Gataiance S; Eltringham-Smith LJ; Bhakta V; Hortelano G; Sheffield WP
Thromb Haemost; 2005 Dec; 94(6):1138-47. PubMed ID: 16411385
[TBL] [Abstract][Full Text] [Related]
2. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits.
Sheffield WP; Mamdani A; Hortelano G; Gataiance S; Eltringham-Smith L; Begbie ME; Leyva RA; Liaw PS; Ofosu FA
Br J Haematol; 2004 Aug; 126(4):565-73. PubMed ID: 15287951
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B.
Kao CY; Lin CN; Yang YL; Hamaguchi N; Yang SJ; Shen MC; Kao JT; Lin SW
Thromb Haemost; 2011 Apr; 105(4):616-26. PubMed ID: 21301787
[TBL] [Abstract][Full Text] [Related]
4. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
[TBL] [Abstract][Full Text] [Related]
5. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
7. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
[TBL] [Abstract][Full Text] [Related]
8. Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX.
Blostein M; Cuerquis J; Galipeau J
Haemophilia; 2007 Nov; 13(6):701-6. PubMed ID: 17973845
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
10. Factor IX: Insights from knock-out and genetically engineered mice.
Monahan PE
Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
12. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice.
Wu YM; Kao CY; Huang YJ; Yu IS; Lee HS; Lai HS; Lee PH; Lin CN; Lin SW
Cell Transplant; 2010; 19(9):1169-80. PubMed ID: 20412633
[TBL] [Abstract][Full Text] [Related]
13. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the factor IX epidermal growth factor-like domain mutation Ile66Thr associated with mild hemophilia B.
Knobe KE; Persson KE; Sjörin E; Villoutreix BO; Ljung RC
Pathophysiol Haemost Thromb; 2006; 35(5):370-5. PubMed ID: 17230038
[TBL] [Abstract][Full Text] [Related]
15. Expression of coagulation factor IX in a haematopoietic cell line.
Rodriguez MH; Enjolras N; Plantier JL; Réa M; Leboeuf M; Uzan G; Bordet JC; Négrier C
Thromb Haemost; 2002 Mar; 87(3):366-73. PubMed ID: 11916066
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of hepatocyte transplantation on hemophilia B.
Tatsumi K; Ohashi K; Shima M; Nakajima Y; Okano T; Yoshioka A
Transplantation; 2008 Jul; 86(1):167-70. PubMed ID: 18622295
[TBL] [Abstract][Full Text] [Related]
17. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
[TBL] [Abstract][Full Text] [Related]
19. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
